Status:
UNKNOWN
Clinical Study on Triple Negative Breast Cancer With Chinese Medicine
Lead Sponsor:
Sheng Liu
Conditions:
Progression-Free-Survival
Recurrence
Eligibility:
FEMALE
18-75 years
Brief Summary
Breast cancer is one of the most serious threat to women's health of malignant tumors, also the most common causes of cancer death in women.Triple-negative breast cancer (TNBC) refers to the immunohis...
Eligibility Criteria
Inclusion
- Participants' inclusion criteria are as follows:
- The primary breast cancer after surgical treatment, the pathological diagnosis of breast epithelial tumors (breast cancer), ER, PR and Her-2 immunohistochemical results were negative;
- no recurrence of metastasis;
- card score ≥ 60 points;
- Female patients aged 18-75 years (including 18,75 years);
- there is no serious organic or functional disorders, no drugs and food allergy;
- willing to receive treatment, observation and inspection.
- Participants' exclusion criteria are as follow:
- does not meet the inclusion criteria;
- patients expected to survive \<6 months;
- combined with cardiovascular and cerebrovascular, liver, kidney, hematopoietic system of serious primary disease and mental illness;
- breastfeeding, pregnancy or women preparing for pregnancy;
- allergies and allergies to a variety of drugs;
- are participating in other drug subjects.
Exclusion
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2019
Estimated Enrollment :
620 Patients enrolled
Trial Details
Trial ID
NCT03332368
Start Date
January 1 2017
End Date
January 1 2019
Last Update
November 7 2017
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, China, 220000
2
Longhua Hosptial
Shanghai, Shanghai Municipality, China, 220000
3
ShuGuang Hospital
Shanghai, Shanghai Municipality, China, 220000
4
Yueyang Hospital
Shanghai, Shanghai Municipality, China, 220000